Anika Therapeutics, Inc.
ANIK · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $135 | $152 | $215 | $240 |
| - Cash | $58 | $53 | $53 | $56 |
| + Debt | $23 | $25 | $25 | $26 |
| Enterprise Value | $100 | $123 | $187 | $210 |
| Revenue | $28 | $28 | $26 | -$1 |
| % Growth | -1.4% | 7.8% | 2,128.5% | – |
| Gross Profit | $16 | $14 | $15 | $23 |
| % Margin | 56% | 50.9% | 56.1% | -1,749.2% |
| EBITDA | -$1 | -$3 | -$3 | $27 |
| % Margin | -3% | -9.8% | -10.3% | -2,056.5% |
| Net Income | -$2 | -$4 | -$5 | -$22 |
| % Margin | -8.4% | -14.1% | -18.6% | 1,695% |
| EPS Diluted | -0.16 | -0.28 | -0.34 | -1.5 |
| % Growth | 42.9% | 17.6% | 77.3% | – |
| Operating Cash Flow | $7 | -$0 | -$0 | $2 |
| Capital Expenditures | -$2 | -$1 | -$3 | -$1 |
| Free Cash Flow | $5 | -$2 | -$3 | $0 |